Mu and delta opioid receptor expressing interneurons are recruited by the TA pathway. by Xavier Rezai (5656768)

“…<p>TA-eIPSCs amplitude is decreased following DAGO 500 nM (A) or deltorphin II 500 nM (B) bath application in DOR-eGFP knock-in mice. *, p<0.05, **, p<0.01 versus baseline or drug respectively. …”

Modeling experimental findings on lamotrigine application. by Michele Migliore (323322)

“…<p>(<i>left</i>) experimental recordings demonstrating a decrease in dendritic (but not somatic) firing after <i>I_h</i> up-regulation caused by application of the anticonvulsive drug Lamotrigine (adapted from Fig. 2d of <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0036867#pone.0036867-Poolos1" target="_blank">[4]</a>); (<i>right</i>) simulation of somatic (<i>bottom</i>) and dendritic (<i>top</i>, ∼200 µm from soma) recordings during a 500 ms current injection of 0.55 or 0.82 nA, respectively, before (control) and during LTG application (bar above plots); <i>g_{h_pk}</i> = 0.01 mS/cm², <i>lk</i> = 0.5 (control), <i>lk</i> = 0.8 (LTG).…”

Contrasted adaptive responses of different <i>Medicago truncatula</i> genotypes to nitrogen availability. by Anouk Zancarini (126528)

“…Group 1 includes DZA315-16 and DZA315-26; Group 2 includes F83005-5 and SA028064; Group 3 includes Jemalong-A17, Jemalong-J6. …”

Histopathology of the hippocampus seven days following Sham or ACA. by Charles H. Cohan (733750)

“…<b>B)</b> Bar graph depicting the number of non-compromised neurons per field to left (LH) or right (RH) hemisphere to their respective groups, where there was a significant decrease in the number non-compromised neurons following ACA in the CA1 region and RH of the subiculum (*<i>p</i><0.05; Sham n = 6 and ACA n = 5).…”

Echocardiography analysis was followed up to 6 weeks of reperfusion to examine the chronic effects of IR injury. by Megumi Eguchi (333410)

“…On the contrary, STZ mice developed concentric hypertrophy as shown by decreased LVEDV, LVESV and increased EF (A,B,C). M-mode image showing the increase in the LV wall and decrease in interstitial space in STZ heart (D). …”

Receptive fields of two neurons in the optic tectum. by Josine Verhaal (400568)

“…The neuron responded with a short delay to black (40 ms) and with a longer delay to white (130 ms) and therefore could be responsive to decrease in luminance. …”

Sequential Injection Analysis of Butyrylcholinesterase Using Butyrylcholine Ion-Selective Electrode Detector (Supporting Information) by Narimasa KOIZUMI (13719592)

“…In the present SIA method using the BuCh-ISE detector based on <i>α</i>-cyclodextrin membrane, BChE in the concentration range of 0.015–0.50 units/mL was determined at a BuCh concentration of 2.0 mmol dm⁻³ and a reaction time of 5.0 min. …”

Naloxone does not block loperamide effects on mechanosensitivity of C-fibers. by Matthias Ringkamp (253465)

“…<p>A) Naloxone pretreatment does not prevent the loperamide (5 µg/10 µl) – induced increase in mechanical thresholds of C-fibers. …”

(Left) The recorded path of 2 coral larva specimens in the olfactometer. by Spencer J. Franks (22320384)

“…<p>Positions are recorded at 5 Hz, and the coordinates are graded in millimeters. …”

Gene function in early mouse embryonic stem cell differentiation-4 by Kagnew Hailesellasse Sene (25572)

Prdm8 alters layer formation in the neocortex. by Mayuko Inoue (516753)

“…<p>In utero electroporation of any one of control (pCAG-IRES-EGFP with pCAG-IRES-Puro; A), or Prdm8 gain-of-function (pCAG-IRES-EGFP with pCAG-Prdm8; B), or Prdm8 loss-of-function (pCAG-IRES-EGFP with pPrdm8sh#629; C) vectors were carried out at E12.5, and the brains were analyzed at P5. …”

Table_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

DataSheet_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

DataSheet_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_3_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_3_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

DataSheet_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”